New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
07:51 EDTDRTXDurata Therapeutics price target raised to $18 from $14 at JMP Securities
JMP Securities increased its price target on Durata ahead of its evaluation of a single dose version of its dalbavancin anti-infection drug. The firm thinks that creating a single dose regimen for the drug will increase its market penetration beginning around 2017. JMP Securities reiterates an Outperform rating on the shares.
News For DRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 15, 2014
10:02 EDTDRTXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:54 EDTDRTXDurata Therapeutics downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
October 14, 2014
10:01 EDTDRTXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:10 EDTDRTXDurata Therapeutics downgraded to Neutral from Outperform at Credit Suisse
Durata Therapeutics (DRTX ) is being acquired by Actavis (ACT) for $23 per share and $5 in contingent value rights and Credit Suisse does not believe a higher bid will emerge.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use